ES2085775T3 - Dosificador-nebulizador para aplicacion por via nasal. - Google Patents

Dosificador-nebulizador para aplicacion por via nasal.

Info

Publication number
ES2085775T3
ES2085775T3 ES93909781T ES93909781T ES2085775T3 ES 2085775 T3 ES2085775 T3 ES 2085775T3 ES 93909781 T ES93909781 T ES 93909781T ES 93909781 T ES93909781 T ES 93909781T ES 2085775 T3 ES2085775 T3 ES 2085775T3
Authority
ES
Spain
Prior art keywords
nebulizer
dispenser
application via
nasal
way
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909781T
Other languages
English (en)
Inventor
Claudia Mattern
Rudiger Hacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowdean Ltd
Original Assignee
Arrowdean Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowdean Ltd filed Critical Arrowdean Ltd
Application granted granted Critical
Publication of ES2085775T3 publication Critical patent/ES2085775T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN SPRAY DOSIFICADOR DISEÑADO PARA APLICACION NASAL, CONTENIENDO EL SPRAY AL MENOS UNA HORMONA SEXUAL, AL MENOS UN PRECURSOR METABOLICO DE UNA HORMONA SEXUAL Y AL MENOS UN DERIVADO DE UNA HORMONA SEXUAL O COMBINACION DE ESTAS, CON LA EXCEPCION DEL PRECURSOR DE TESTOSTERONA, O AL MENOS UNA AMINA BIOGENICA, CON LA EXCEPCION DE CATECOLAMINA.
ES93909781T 1992-06-03 1993-05-17 Dosificador-nebulizador para aplicacion por via nasal. Expired - Lifetime ES2085775T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924218291 DE4218291A1 (de) 1992-06-03 1992-06-03 Dosierspray für pernasale Applikation

Publications (1)

Publication Number Publication Date
ES2085775T3 true ES2085775T3 (es) 1996-06-01

Family

ID=6460299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909781T Expired - Lifetime ES2085775T3 (es) 1992-06-03 1993-05-17 Dosificador-nebulizador para aplicacion por via nasal.

Country Status (6)

Country Link
EP (1) EP0643575B1 (es)
JP (1) JP3705600B2 (es)
CA (1) CA2135203C (es)
DE (2) DE4218291A1 (es)
ES (1) ES2085775T3 (es)
WO (1) WO1993024107A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735293A1 (en) * 1995-01-17 1996-07-18 Menuco Corp. Nadh and nadph therapeutic agents for dermal administration
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
PT2068825E (pt) 2006-10-04 2011-02-11 M & P Patent Ag Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6033M (es) 1967-02-10 1968-05-13
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
EP0536204B1 (en) * 1990-06-27 1994-04-06 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5116847A (en) * 1991-01-25 1992-05-26 The Procter & Gamble Company Use of loperamide and related compounds for treatment of respiratory disease symptoms
DE4214953C2 (de) * 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels

Also Published As

Publication number Publication date
WO1993024107A1 (de) 1993-12-09
CA2135203A1 (en) 1993-12-09
JPH07507279A (ja) 1995-08-10
DE59301810D1 (de) 1996-04-11
JP3705600B2 (ja) 2005-10-12
EP0643575A1 (de) 1995-03-22
DE4218291A1 (de) 1993-12-09
CA2135203C (en) 1998-12-29
EP0643575B1 (de) 1996-03-06

Similar Documents

Publication Publication Date Title
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
ES2085775T3 (es) Dosificador-nebulizador para aplicacion por via nasal.
TR199901669T2 (xx) Erkeklerdeki ereksiyon probleminin tedavisi i�in gerekli dozaj �ekilleri ve metod.
PT83873A (de) Arzneimittel mit antitumorwirkung
FI95768C (fi) Emättimensisäinen antosysteemi
ES2152608T3 (es) Preparacion medicinal que contiene un gas noble lipofilo.
BR9202675A (pt) Processo e aparelho para distribuir um material polente cosmeticamente ativo para o corpo,composicao eletrostaticamente pulverizavel,e.uso de uma pulverizacao eletrostatica
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
ES2056660T3 (es) Forma de dosificacion para pautas de suministro de farmacos variables con el tiempo.
SE9201718D0 (sv) Nasal spray device
NO303540B1 (no) Sulfonylalkanoylamino-hydroksyetylaminosulfonamider som er nyttige som retrovirale proteaseinhibitorer, farmas°ytiske preparater inneholdende forbindelsene samt anvendelse av forbindelsene for fremstilling av medikamenter
TW200626613A (en) Analogues of GLP-1
MX9203755A (es) Dispositivo de suministro iontoforetico de drogas o agentes terapeuticos, dotado de un adhesivo de electrotransporte.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
MX9303376A (es) Utilizacion de metilhidroxietil- o metilhidroxipropil-(eteres de celulosa)carboximetilados.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
ATE63811T1 (de) Verwendung von trans-4-((2-amino-3,5-dibrombenzyl)-amino>cyclohexanol.
ES2191206T3 (es) Nueva utilizacion de la creatina.
ES2126760T3 (es) Nuevo ansiolitico.
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 643575

Country of ref document: ES